X4 Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
X4 Pharmaceuticals's earnings have been declining at an average annual rate of -21.1%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 38.1% per year.
Key information
-21.1%
Earnings growth rate
77.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -38.1% |
| Return on equity | -198.0% |
| Net Margin | n/a |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16X4 Pharmaceuticals EPS misses by $0.12
Nov 05Revenue & Expenses BreakdownBeta
How X4 Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -101 | 36 | 72 |
| 30 Sep 23 | 0 | -111 | 32 | 76 |
| 30 Jun 23 | 0 | -131 | 30 | 71 |
| 31 Mar 23 | 0 | -96 | 27 | 69 |
| 31 Dec 22 | 0 | -96 | 27 | 61 |
| 30 Sep 22 | 0 | -103 | 28 | 54 |
| 30 Jun 22 | 0 | -102 | 27 | 53 |
| 31 Mar 22 | 0 | -100 | 27 | 53 |
| 31 Dec 21 | 0 | -103 | 25 | 51 |
| 30 Sep 21 | 0 | -85 | 23 | 51 |
| 30 Jun 21 | 0 | -82 | 23 | 49 |
| 31 Mar 21 | 0 | -78 | 22 | 45 |
| 31 Dec 20 | 3 | -62 | 21 | 42 |
| 30 Sep 20 | 3 | -55 | 19 | 37 |
| 30 Jun 20 | 3 | -55 | 18 | 34 |
| 31 Mar 20 | 3 | -53 | 18 | 33 |
| 31 Dec 19 | 0 | -53 | 18 | 30 |
| 30 Sep 19 | 0 | -55 | 17 | 28 |
| 30 Jun 19 | 0 | -46 | 15 | 25 |
| 31 Mar 19 | 0 | -40 | 12 | 21 |
| 31 Dec 18 | 0 | -36 | 9 | 20 |
| 30 Sep 18 | 0 | -31 | 7 | 19 |
| 31 Dec 17 | 0 | -25 | 5 | 17 |
Quality Earnings: XFOR is currently unprofitable.
Growing Profit Margin: XFOR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XFOR is unprofitable, and losses have increased over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare XFOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XFOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: XFOR has a negative Return on Equity (-197.98%), as it is currently unprofitable.